Facial Injectable Market: Set for Rapid Growth and Trend by 2025

Changing perception of beauty all over the world is demanding the increased use of dermal fillers and other facial injectable. Some of the trending applications of facial injectable include facial rejuvenation and bio-engineering of the facial skin, raising scar depressions and many other. Even though the surgical rejuvenation has been the choice of treatment by people, surgeons now a days are preferring facial dermal fillers as a complementary to surgical procedures such as face lift. Throughout the history of facial injectable many techniques have been introduced for facial rejuvenation. Above these all collagen injections are being used for decades as a dermal filler to treat facial imperfections.

However, the introduction of synthetic calcium hydroxylapatite fillers in global facial injectable market has changed the market trends overtime. Because of synthetic nature of calcium hydroxylapatite fillers, these products show more durability as compared to natural collagen fillers and thus provide deep dermal effects. Some of the commercially available dermal fillers are Radiesse – synthetic calcium hydroxylapatite cohesive subdermal injectable implant, manufactured by Merz North America Inc., Restylane – hyaluronic acid fillers with range of applications, EVOLENCE Collagen Filler, Juvederm – hyaluronic acid injectable gel, Dysport – abobotulinumtoxinA and others.

The global market for facial injectable is expected to be driven by increasing demand from middle age & growing urban population and raising esthetic standards. The target age group for these products is women age between35 to 60 years. However, both men and women are using these products to achieve and retain the youthful appearance. Adoption of dermal fillers across the world is different due to obvious differences in factors such as geographic location, life style and socioeconomic conditions, ethnicity etc. Legal and regulatory issues and safety concerns of certain injectable products such as boltulinum toxin A will remain substantial restraints for the global facial injectable market. In the U.S., injectable facial fillers are considered as Class III medical device, meaning they pose high risk to patient safety.

Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/14350

As on now, facial injectable are approved for use in indications such as correction of moderate to severe facial folds and wrinkles, lip augmentation and dermal implantation for correction of perioral rhytids, cheek augmentation, correction of nasolabial folds, correction of acne and depressed cutaneous scars etc. However, the off-label use of facial injectable in countries such as Japan, India, and some of the European countries would drive the growth of global market for facial injectable.

Based on product type, the global facial injectable market has been classified as dermal fillers or injectable implants (further classified as hyaluronic acid fillers, collagen fillers and synthetic fillers) and anti-aging/ anti-wrinkle injections (further classified as botulinum toxin A and poly-L-lactic acid (PLLA) micro particles). Among dermal fillers, collagen fillers are expected to hold highest market share due to high adoption rate.

Based on end user, the global facial injectable market has been classified as hospitals, dermatology clinics, beauty clinics and dermatology research institutes. Dermatology clinics and beauty clinics are expected to hold major share in global market for facial injectable.

On the basis of regional presence, global facial injectable market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Europe is expected to lead the global market while North America is expected to hold second largest market share in global facial injectable market. In the U.S. facial injectable such as dermal fillers are considered as a medical device and are covered under prescription products. Whereas in Europe facial injectable are considered as a non-prescription products which allows the widespread use of them. Asia Pacific market for facial injectable is expected to grow at significant CAGR over the forecast period owing to increasing beauty concern among mid-age population.

Request Report For TOC @ https://www.persistencemarketresearch.com/toc/14350

Some of the players operating in global facial injectable market are Advanced Dermatology, Merz, Inc., Galderma Laboratories, L.P., ColBar LifeScience Ltd., Allergan, Plc., Valeant Pharmaceuticals North America LLC., Sanofi Biosurgery Inc. (Sanofi), Anika Therapeutics, Inc., Suneva Medical, Inc. and others. Distribution agreements between the global and regional players in the global facial injectable market is emerging as the prominent trend overtime. For instance, Galderme Laboratories distributed Valeant Pharmaceuticals’ Restylane line of products in the U.S. and Canada.

About Us

Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research Pvt. Ltd

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web:www.persistencemarketresearch.com

This release was published on openPR.